What was known before {#section21-2054358117699822}
=====================

Vitamin D3 is made in the skin from 7-dehydrocholesterol under the influence of ultraviolet light. Vitamin D is metabolized to 25-hydroxyvitamin D and then to the 1,25-dihydroxyvitamin D via 1-alpha-hydroxylase found predominately in the kidney. 1,25-dihydroxyvitamin D is the ligand for the vitamin D receptor that is found on multiple cell types of cells in the immune system. Stimulation of the receptors appears to lead to a more tolerogenic phenotype that might decrease the risk of acute kidney transplant rejection. This hypothesis is supported by studies in animals but the results in humans have been inconclusive.

What this adds {#section22-2054358117699822}
==============

We have shown that low serum concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D are not associated with an increased risk of acute rejection following kidney transplantation.

Introduction {#section23-2054358117699822}
============

Kidney transplantation is the treatment of choice for end-stage renal disease as it prolongs survival,^[@bibr1-2054358117699822]^ improves quality of life, and is less costly when compared with dialysis.^[@bibr2-2054358117699822]^ However, the full potential of this treatment option is not being realized as many kidney transplants fail prematurely. Although there has been a significant reduction in the risk of acute rejection over the last several decades,^[@bibr3-2054358117699822]^ the occurrence and severity of acute rejection remain strong predictors of long-term graft outcome.^[@bibr4-2054358117699822]^ Several risk factors for acute rejection have been identified and include the number of human leukocyte antigen (HLA) mismatches, delayed graft function, deceased donor, repeat transplant, panel reactive antibody level, race, and female gender.^[@bibr5-2054358117699822][@bibr6-2054358117699822]-[@bibr7-2054358117699822]^ However, predicting acute rejection in the individual patient remains imperfect, which suggests that other, yet undiscovered, factors may be important.

The vitamin D receptor is found in most cell types of the immune system including macrophages, dendritic cells, CD4+ T cells, and CD8+ T cells.^[@bibr8-2054358117699822]^ 1,25-Dihydroxyvitamin D has been shown to inhibit antigen stimulated T-cell proliferation as well as inhibit the production of interleukin-2 (IL-2), IL-12, and gamma interferon.^[@bibr9-2054358117699822],[@bibr10-2054358117699822]^ Furthermore, 1,25-dihydroxyvitamin D can direct naïve CD4+ cells toward a T~h~2 phenotype, which may be important in allograft tolerance.^[@bibr8-2054358117699822]^ Patients with chronic kidney disease are known to be deficient in both 1,25-dihydroxyvitamin D^[@bibr11-2054358117699822]^ and 25-hydroxyvitamin D,^[@bibr12-2054358117699822][@bibr13-2054358117699822]-[@bibr14-2054358117699822]^ but the impact of these deficiencies on the risk of acute rejection after kidney transplantation remains speculative.

The objective of this study was to determine the association between serum 1,25-dihydroxyvitamin D and serum 25-hydroxyvitamin D concentrations and the risk of biopsy-proven acute rejection (BPAR) following kidney transplantation.

Materials and Methods {#section24-2054358117699822}
=====================

Study Population {#section25-2054358117699822}
----------------

This was a multi-center, prospective cohort study from 3 academic kidney transplant programs (Ottawa, London, Toronto--University Health Network) in Ontario, Canada, from August 2007 to December 2014. We included all consecutive adult patients at the 3 institutions who received a solitary kidney transplant from August 1, 2007, to December 29, 2012, were able to provide written informed consent, and planned to be followed at the same center post-operatively. The study was approved by the Research Ethics Board at each institution. The study was carried out according to the Declaration of Helsinki and Declaration of Istanbul. Demographic data, past medical history, potential risk factors for acute rejection, and immunosuppression were collected on each individual at the time of transplantation. Study visits occurred at baseline, 3 months, 6 months, and 12 months post-transplantation.

Immunosuppression Protocol {#section26-2054358117699822}
--------------------------

Immunosuppression for low immunological risk patients typically included basiliximab or anti-thymocyte globulin (total dose 3 mg/kg) plus methylprednisolone for induction followed by tacrolimus, mycophenolate mofetil, and prednisone for maintenance therapy. For patients at high risk to develop diabetes mellitus, cyclosporine was used instead of tacrolimus. Basiliximab or low-dose anti-thymocyte globulin was substituted with high-dose anti-thymocyte globulin (total dose of 5-7 mg/kg) for high-risk patients and those with delayed graft function.

Measurement of Vitamin D {#section27-2054358117699822}
------------------------

Samples for 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were collected at baseline (immediately pre-transplant), 3 months, and 6 months post-transplantation and stored at −80°C until analyzed. The investigators were unaware of the results. Serum 25-hydroxyvitamin D concentration was measured using an antibody-based radioimmunoassay (DiaSorin Inc, Stillwater, Minnesota, USA). This method detects both 25-hydroxyvitamin D~3~ (cholecalciferol, produced in vivo) and 25-hydroxyvitamin D~2~ (ergocalciferol, contained in foods and 25-hydroxyvitamin D supplements) on an equimolar basis, therefore providing an accurate measure of true 25-hydroxyvitamin D status.^[@bibr15-2054358117699822]^ The level of agreement and correlation between the DiaSorin radioimmunoassay and high-performance liquid chromatography methods was excellent.^[@bibr16-2054358117699822],[@bibr17-2054358117699822]^ The coefficient of variation (CV) for the radioimmunoassay was 10% to 12% in the range of 35 to 150 nmol/L. The 1,25-dihydroxyvitamin D analysis was performed by semi-automated enzyme immunoassay (IDS, Immunodiagnostic Systems, United Kingdom) that involved extraction of 1,25-dihydroxyvitamin D from potential cross-reactants by incubation with a solid-phase monoclonal antibody followed by an enzyme-linked immunosorbent assay. Briefly, the immuno-extraction gel was washed and purified; 1,25-dihydroxyvitamin D was eluted off and incubated overnight with a highly specific anti-1,25-dihydroxyvitamin D antibody. 1,25-Dihydroxyvitamin D linked--biotin was added followed by enzyme-labeled (horseradish peroxidase) avidin. The microtiter plate was read using a Perkin Elmer VICTOR3 V (Waltham, Massachusetts) plate reader at 450 nm (reference 650 nm). The CV was less than 13% at all levels. All commonly available vitamin D supplements, including vitamin D3 (cholecalciferol), alfacalcidol, and calcitriol, available in our renal transplant centers are detected with these 2 assays.

Outcomes {#section28-2054358117699822}
--------

The primary outcome was the time from kidney transplantation to the first occurrence of BPAR within the first-year post-transplant. Kidney transplant biopsies were all performed for indication and were classified as per the Banff criteria.^[@bibr18-2054358117699822]^

Statistical Analysis {#section29-2054358117699822}
--------------------

Based on an anticipated BPAR rate of 12% and a power of 80%, we estimated that 310 participants would be required to detect a relative risk of 1.5 for acute rejection in patients with the lowest levels versus the highest levels of the vitamin D metabolites.

Baseline characteristics of the study participants were summarized for the cohort. For 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, the mean, standard deviation, median, and interquartile range were reported. In addition, the proportion of participants who had vitamin D deficiency (25-hydroxyvitamin D level \<50 nmol/L) and vitamin D insufficiency (25-hydroxyvitamin D level 50-75 nmol/L) were determined according to the Endocrine Society guidelines.^[@bibr19-2054358117699822]^

Extended Kaplan-Meier plots for time to first BPAR were created incorporating the time-varying nature of the serum concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (by tertiles).^[@bibr20-2054358117699822]^ Comparisons of the survival functions between the groups were made using the log-rank test. Cox proportional hazards models were used to analyze time to first BPAR accounting for the time-varying nature of the serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D (ie, the vitamin D measurement used in the model was always the value preceding the acute rejection). In these time-dependent Cox models, vitamin D status was handled in the following ways: (1) as a time-dependent continuous variable and (2) by tertiles of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Other covariates that were considered included age, sex, body mass index, race, pre-emptive transplantation, time on dialysis pre-transplant, donor type (living or deceased), repeat transplantation, delayed graft function, immunosuppressive medications, panel reactive antibody, and the number of HLA mismatches. Univariable analyses are presented first followed by a multivariable model adjusted for variables that have been associated with both acute rejection and vitamin D status (age, sex, body mass index, race, and time on dialysis). As serum vitamin D "sufficiency" status has not been defined from an immunological perspective, the univariable and multivariable models were repeated with the serum 25-hydroxyvitamin D level less than 25 nmol/L versus a level higher than or equal to 25 nmol/L. Missing 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations were excluded from the analysis, and no imputation was used. A 2-sided *P* value less than .05 was considered statistically significant. All analyses were performed using SAS statistical software, Version 9.3.

Results {#section30-2054358117699822}
=======

From 556 screened patients, 338 patients were enrolled, and 327 patients were included in the analytic cohort ([Figure 1](#fig1-2054358117699822){ref-type="fig"}). The mean (SD) age was 51 (14) years. Participants were mostly male (67%) and white (84.9%; [Table 1](#table1-2054358117699822){ref-type="table"}). The most common causes of end-stage renal disease were glomerulonephritis, other and diabetes mellitus. The majority of patients were first-time transplants (88%). At the time of transplant, approximately 60% of patients were taking some type of vitamin D supplement. Although these medications were not continued immediately post-transplant, 27, 3, and 9 patients were taking vitamin D3, alfacalcidol, or calcitriol, respectively, in follow-up ([Table 1](#table1-2054358117699822){ref-type="table"}). Most patients (86.9%) received induction immunosuppression, with similar proportions receiving basiliximab and anti-thymocyte globulin ([Table 1](#table1-2054358117699822){ref-type="table"}). The most common maintenance immunosuppression regimen included tacrolimus, mycophenolate, and prednisone. During follow-up, 4 patients were switched from tacrolimus to cyclosporine and 5 patients were switched from mycophenolate to azathioprine. Five patients were treated with sirolimus, 2 with leflunomide, and 1 patient received a combination of cyclophosphamide, rituximab, and eculizumab.

![Flow diagram of patients in the study.](10.1177_2054358117699822-fig1){#fig1-2054358117699822}

###### 

Baseline Characteristics of the Study Population.

![](10.1177_2054358117699822-table1)

  Baseline characteristics                  n (%)
  ----------------------------------------- ----------------
  Age, y; mean (SD)                         50.5 (13.8)
  Female gender                             108 (33%)
  Body mass index; mean (SD)                27 (5)
  Race                                      
   Caucasian                                275 (84.9)
   Black                                    14 (4.3)
   Other                                    13 (4.0)
   Aboriginal                               11 (3.4)
   Asian                                    10 (3.1)
   Latin American                           1 (0.3)
  Primary etiology of renal disease         
   Glomerulonephritis                       69 (21.1)
   Other                                    69 (21.1)
   Diabetes mellitus                        68 (20.8)
   Polycystic kidney disease                46 (14.1)
   Hypertension                             27 (8.3)
   Unknown                                  15 (4.6)
  Primary transplant                        288 (88.3)
  Ever receive renal replacement therapy    269 (82.8)
  Dialysis vintage; median (IQR), days      829 (391-1450)
  PRA Class I                               
   0                                        178
   1-20                                     113
   \>20                                     36
  PRA Class II                              
   0                                        156
   1-20                                     104
   \>20                                     67
  HLA mismatch                              
   4-6                                      197 (61.2)
   1-3                                      96 (29.8)
   0                                        29 (.0)
  Vitamin D (immediately pre-transplant)    194 (59.5)
   Calcitriol                               108 (33.0)
   Alfacalcidol                             66 (20.2)
   Cholecalciferol                          28 (8.6)
   Other                                    17 (5.2)
   Doxercalciferol                          1 (0.3)
   Ergocalciferol                           1 (0.3)
  Living donor                              151 (46.1)
  Delayed graft function                    17 (5.2)
  Immunosuppressant medications (initial)   
   Intravenous methylprednisolone           325 (99.0)
   Prednisone                               309 (94.8)
   Induction therapy                        
    Basiliximab                             136 (41.6)
    Anti-thymocyte globulin                 148 (45.3)
    Neither                                 43 (13.2)
   Calcineurin inhibitor                    
    Tacrolimus                              282 (86.2)
    Cyclosporine                            40 (12.2)
    Neither                                 5 (1.5)
   Anti-metabolite                          
    Mycophenolate mofetil                   302 (92.4)
    Mycophenolate sodium                    21 (6.4)
    Neither                                 4 (1.2)
   IVIG                                     31 (9.5)
   Pre-transplant plasmapheresis            12 (3.7)
   Other                                    10 (3.1)

*Note.* SD = standard deviation; IQR = interquartile range; PRA = panel reactive antibody; HLA = human leukocyte antigen; IVIG = intravenous immunoglobulin.

The mean (SD) serum concentration of 25-hydroxyvitamin D at the time of transplant was 64.3 (30.4) nmol/L; 36% of patients were classified as deficient and 30% insufficient ([Table 2](#table2-2054358117699822){ref-type="table"}). The concentration of 25-hydroxyvitamin D remained stable over time ([Figure 2](#fig2-2054358117699822){ref-type="fig"}). The mean (SD) serum concentration of 1,25-dihydroxyvitamin D at the time of transplant was 22.5 (22.1) pmol/L and increased approximately 3.5-fold over the first 6 months post-transplant ([Table 2](#table2-2054358117699822){ref-type="table"}, [Figure 3](#fig3-2054358117699822){ref-type="fig"}).

###### 

25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Serum Concentration Over Time.

![](10.1177_2054358117699822-table2)

                                     Baseline      3 months      6 months
  ---------------------------------- ------------- ------------- -------------
  25-hydroxyvitamin D (nmol/L)                                   
   N                                 307           301           293
   Mean (SD)                         64.3 (30.4)   63.5 (25.9)   67.0 (27.6)
   Median (IQR)                      59 (40-85)    60 (47-77)    63 (49-87)
                                                                 
  25-hydroxyvitamin D (nmol/L)       N (%)         N (%)         N (%)
   Deficient                         111 (36)      91 (30)       79 (27)
   Insufficient                      91 (30)       127 (42)      112 (38)
   Sufficient                        105 (34)      83 (28)       102 (35)
                                                                 
  1,25-dihydroxyvitamin D (pmol/L)                               
   N                                 298           272           262
   Mean (SD)                         22.5 (22.1)   74.5 (35.3)   85.6 (41.3)
   Median (IQR)                      14 (8-29)     73 (50-95)    82 (54-105)

*Note.* SD = standard deviation; IQR = interquartile range.

![Box and Whisker plots of the change in serum concentration of 25-hydroxyvitamin D post-transplant.](10.1177_2054358117699822-fig2){#fig2-2054358117699822}

![Box and Whisker plots of the change in serum concentration of 1,25-dihydroxyvitamin D post-transplant.](10.1177_2054358117699822-fig3){#fig3-2054358117699822}

First BPAR occurred in 54 (16.5%) patients. By extended Kaplan-Meier analysis, time to first BPAR was not significantly different across tertiles of serum 25-hydroxyvitamin D (log-rank *P* = .93; [Figure 4](#fig4-2054358117699822){ref-type="fig"}) or 1,25-dihydroxyvitamin D (log-rank *P* = .25; [Figure 5](#fig5-2054358117699822){ref-type="fig"}). In univariate analysis, a lack of induction therapy was associated with an increased risk of acute rejection ([Table 3](#table3-2054358117699822){ref-type="table"}). Lower levels of HLA mismatch were associated with a decreased risk of acute rejection. The serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were not associated with acute rejection either as continuous variables or divided into tertiles ([Table 3](#table3-2054358117699822){ref-type="table"}).

![Extended Kaplan-Meier curve of the association between tertiles of 25-hydroxyvitamin D serum concentration and time to acute rejection.\
*Note.* 25-hydroxyvitamin D: 0, lowest tertile; 1, middle tertile; 2, highest tertile.](10.1177_2054358117699822-fig4){#fig4-2054358117699822}

![Extended Kaplan-Meier curve of the association between tertiles of 1,25-dihydroxyvitamin D serum concentration and time to acute rejection.\
*Note.* 1,25-dihydroxyvitamin D: 0, lowest tertile; 1, middle tertile; 2, highest tertile.](10.1177_2054358117699822-fig5){#fig5-2054358117699822}

###### 

Univariate Risk Factors for Time to First Episode of Acute Rejection.

![](10.1177_2054358117699822-table3)

  Potential risk factors                          HR (95% CI)        *P* value
  ----------------------------------------------- ------------------ -----------
  Age                                             0.99 (0.97-1.01)   .31
  Sex (male vs female---REF)                      1.42 (0.77-2.60)   .26
  Body mass index                                 1.04 (0.98-1.10)   .17
  Race (white vs other---REF)                     1.22 (0.55-2.69)   .63
  Pre-emptive transplantation (yes vs no---REF)   1.41 (0.64-3.12)   .40
  Time on dialysis pre-transplant (per month)     0.99 (0.99-1.01)   .81
  Donor type (deceased vs living---REF)           1.07 (0.63-1.84)   .79
  Repeat transplantation (yes vs no---REF)        0.79 (0.37-1.66)   .53
  Delayed graft function (yes vs no---REF)        0.79 (0.11-5.69)   .81
  Induction                                                          
   Basiliximab                                    REF                REF
   Anti-thymocyte globulin                        1.50 (0.82-2.77)   .19
   Neither                                        2.24 (1.05-4.78)   .04
  Calcineurin inhibitor                                              
   Tacrolimus                                     REF                REF
   Cyclosporine                                   0.54 (0.20-1.51)   .24
  Anti-metabolite                                                    
   Mycophenolate mofetil                          REF                REF
   Mycophenolate sodium                           0.80 (0.25-2.56)   .71
  IVIG (yes vs no)                                1.02 (0.41-2.56)   .97
  Pre-transplant plasmapheresis (yes vs no)       2.50 (0.90-6.92)   .08
  PRA Class I                                                        
   0                                              REF                REF
   1-20                                           0.76 (0.41-1.41)   .38
   \>20                                           1.55 (0.74-3.26)   .25
  PRA Class II                                                       
   0                                              REF                REF
   1-20                                           0.91 (0.49-1.69)   .76
   \>20                                           1.32 (0.54-3.20)   .55
  HLA mismatch                                                       
   4-6                                            REF                REF
   1-3                                            0.49 (0.24-0.97)   .04
   0                                              0.49 (0.15-1.58)   .23
  25-hydroxyvitamin D (per 10 nmol/L)             1.01 (0.92-1.12)   .79
  25-hydroxyvitamin D (by tertile)                                   
   Highest (74-186 nmol/L)                        REF                REF
   Middle (51-73 nmol/L)                          1.04 (0.51-2.11)   .92
   Lowest (4-50 nmol/L)                           1.13 (0.58-2.23)   .72
  25-hydroxyvitamin D                                                
   ≥25nmol/L                                      REF                0.51
   \<25nmol/L                                     1.48 (0.46-4.78)   
  1,25-dihydroxyvitamin D (per 10 pmol/L)         0.95 (0.86-1.06)   .38
  1,25-dihydroxyvitamin D (by tertile)                               
   Highest (77-226 pmol/L)                        REF                REF
   Middle (31-76 pmol/L)                          2.24 (0.85-5.94)   .10
   Lowest (4-30 pmol/L)                           2.12 (0.70-6.44)   .19

*Note.* HR = hazard ratio; CI = confidence interval; REF = reference group; IVIG = intravenous immunoglobulin; PRA = panel reactive antibody; HLA = human leukocyte antigen.

In a multivariable model, adjusting for variables that have been previously associated with both acute kidney transplant rejection and vitamin D status (age, sex, body mass index, and time on dialysis) did not alter the results ([Table 4](#table4-2054358117699822){ref-type="table"}).

###### 

Multivariable Model Adjusting for Variables Associated With Acute Rejection and Vitamin D Status.

![](10.1177_2054358117699822-table4)

                                            HR (95% CI)         *P* value
  ----------------------------------------- ------------------- -----------
  25-hydroxyvitamin D (per 10 nmol/L)       0.996 (0.87-1.14)   .96
  25-hydroxyvitamin D (by tertile)                              
   Highest (74-186 nmol/L)                  REF                 REF
   Middle (51-73 nmol/L)                    1.33 (0.49-3.59)    .57
   Lowest (4-50 nmol/L)                     1.25 (0.49-3.17)    .64
  25-hydroxyvitamin D                                           
   ≥25nmol/L                                REF                 .51
   \<25nmol/L                               1.64 (0.37-7.18)    
  1,25-dihydroxyvitamin D (per 10 pmol/L)   0.97 (0.84-1.12)    .64
  1,25-dihydroxyvitamin D (by tertile)                          
   Highest (77-226 pmol/L)                  REF                 REF
   Middle (31-76 pmol/L)                    1.44 (0.39-5.34)    .58
   Lowest (4-30 pmol/L)                     2.25 (0.51-9.84)    .28

*Note.* HR = hazard ratio; CI = confidence interval; REF = reference group.

Discussion {#section31-2054358117699822}
==========

In this large prospective cohort study of kidney transplant recipients, the serum concentrations of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D at baseline were 64.3 (30.4) nmol/L and 22.5 (22.1) pmol/L, respectively, such that the majority of patients were not vitamin D sufficient as defined for optimal bone health. In the 6 months after kidney transplant, the serum concentration of 25-hydroxyvitamin D remained unchanged but the serum concentration of 1,25-dihydroxyvitamin D increased approximately 3.5 fold from baseline. In the analysis where time-varying concentrations of the vitamin D metabolites were accounted for, 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were not associated with a decreased risk of BPAR in the first year after kidney transplantation.

Vitamin D levels fall with the declining glomerular filtration rate.^[@bibr21-2054358117699822]^ Mild to moderate renal functional impairment and elevated fibroblast growth factor--23 lead to a reduction in 1-alpha-hydroxylase activity, which is responsible for the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D.^[@bibr22-2054358117699822]^ After kidney transplantation, avoidance of sun exposure and immunosuppressive medications may lead to further reductions in vitamin D.^[@bibr21-2054358117699822]^ In our study, greater than 50% of patients had less than sufficient 25-hydroxyvitamin D serum levels as defined by Endocrine Society guidelines. However, this 25-hydroxyvitamin D concentration was higher than that reported in several other studies of kidney transplant recipients.^[@bibr23-2054358117699822][@bibr24-2054358117699822]-[@bibr25-2054358117699822]^ The reasons for this are unclear as a minority of patients were taking cholecalciferol supplements. The serum concentration of 1,25-dihydroxyvitamin D at baseline was also low despite greater than 50% of patients being treated pre-transplant with the active vitamin D supplement calcitriol or alfacalcidol. These latter results are consistent with similar studies reported in the literature.^[@bibr25-2054358117699822],[@bibr26-2054358117699822][@bibr27-2054358117699822]-[@bibr28-2054358117699822]^

Vitamin D has important immunomodulatory functions that may affect the risk of acute rejection post kidney transplant through diverse effects on T-cell and dendritic cell function.^[@bibr22-2054358117699822]^ However, the effect of vitamin D on the risk of acute kidney transplant rejection reported in the literature is conflicting likely secondary to the different patient populations, sample sizes, different vitamin D assays, assessment time frames, and definition of outcomes. In the current study, the serum concentration of 25-hydroxyvitamin D analyzed as a time-varying continuous variable was not associated with time to first acute kidney transplant rejection. Furthermore, analysis by population tertiles did not alter the conclusions. Our results are similar to those of Bienaime et al, in which the 25-hydroxyvitamin D level at 3 months was not associated with the risk of acute kidney transplant rejection.^[@bibr23-2054358117699822]^ Our results are different from those of Kim et al in which the 25-hydroxyvitamin D level less than 25 nmol/L measured pre-transplant was associated with a greater risk of acute rejection.^[@bibr25-2054358117699822]^ Their patient population differed from ours in many important ways but it is unclear what the effect of differences in "case-mix" might have on immune function.

In a patient population more similar to ours, Lee at al reported an association between the 25-hydroxyvitamin D level less than 50 nmol/L within 30 days post-transplant and the risk of acute rejection at 1 year.^[@bibr24-2054358117699822]^ However, over half of the 25-hydroxyvitamin D--deficient patients were started on vitamin D supplements within 90 days of transplantation. Only those patients who were supplemented with 1,25-dihydroxyvitamin D rather than 25-hydroxyvitamin D experienced a reduction in the risk of acute rejection. It is possible that 1,25-dihydroxyvitamin D is the important immune modulator and that ongoing impairment of the conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D after kidney transplant negates the usefulness of 25-hydroxyvitamin, especially for patients with reduced kidney transplant function. Vitamin D levels were not measured again during that study such that the hypothesis remains speculative and is not supported by our study. We were unable to show an association between the serum concentration of 1,25-dihydroxyvitamin D and risk of BPAR. Although the patients in the lowest tertile of serum 1,25-dihydroxyvitmain D appear to be at increased risk of acute rejection, these results were not statistically significant. Furthermore, in a multivariable model where we controlled for variables that have been associated with both acute rejection and vitamin D status, the conclusions were unchanged. Our results are consistent with two smaller studies. Higher serum calcitriol levels in one study and calcitriol supplementation in the other study were not associated with a decreased risk of acute rejection.^[@bibr28-2054358117699822],[@bibr29-2054358117699822]^

The strengths of our study include the prospective design and inclusion of patients from 3 different academic kidney transplant programs in Canada. Only biopsy-proven acute kidney transplant rejection episodes were included in the analysis thereby excluding other potential causes of an increase in serum creatinine. The assays for the determination of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were consistent for all patients, each done in only 1 laboratory. Our analysis also took into account changes in serum vitamin D concentration over time such that the vitamin D concentrations prior to the episode of acute rejection were used in the analysis to address the time dependency of vitamin D levels over follow-up.

Limitations should be noted. First, we did have a small percentage of patients with missing lab samples. Second, multivariable models were used to improve the validity of the inferences made from the data but residual confounding cannot be completely excluded. Third, it is possible that we missed a potentially clinically important association between vitamin D metabolites and the risk of BPAR due to our sample size that would have affected our statistical power. Finally, the study represents the experience of 3 kidney transplant centers in Ontario, Canada, and may thus not be fully generalizable to other settings.

In summary, a low serum concentration of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D was not associated with an increased risk of acute rejection following kidney transplantation. A larger prospective cohort study and/or clinical trial may be necessary to elucidate a small but potentially meaningful relationship between vitamin D and the risk of BPAR in kidney transplant recipients.
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